ArticleFuture science OA2025
The expression and prognostic predictive value of PD-L2 in patients undergoing radical gastric cancer surgery.
Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinicopathological features and prognoses of HER-2-positive gastric cancer.Molecular and clinical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe expression and prognostic predictive value of programmed death-ligand 2 (PD-L2) in patients undergoing radical gastric cancer (GC) surgery remains unclear.
methodsPD-L2 expression in tumor cells (TC) and tumor-infiltrating immune cells (TIIC) was evaluated by immunohistochemistry. Kaplan-Meier and Cox models were used to evaluate the association of PD-L2 with disease-free survival (DFS) and overall survival (OS).
resultsThis study included 299 patients and the average age was 63.76 ± 11.83 years, with 218 males (72.91%) and 81 females (27.09%). TC PD-L2 expression was significantly associated with poorer DFS (HR = 2.177, 95% CI 1.364-3.474, P = 0.001) and OS (HR = 1.943, 95% CI 1.191-3.169, P = 0.008). Multivariate analysis confirmed TC PD-L2 expression as an independent poor prognostic factor for DFS (HR = 2.121, 95% CI 1.325-3.393, P = 0.002) and OS (HR = 1.812, 95% CI 1.109-2.961, P = 0.018). PD-L2 in TIIC did not correlate with survival. Other poor prognostic factors included age ≥60, vascular invasion, advanced postoperative stage, and HER2 positivity.
conclusionsPD-L2 expression in TC is an independent prognostic biomarker in GC, linked to poorer DFS and OS, suggesting its potential for identifying high-risk patients for personalized therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.